E. Mamounas

4.1k total citations · 3 hit papers
19 papers, 2.6k citations indexed

About

E. Mamounas is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, E. Mamounas has authored 19 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 9 papers in Oncology and 9 papers in Genetics. Recurrent topics in E. Mamounas's work include Breast Cancer Treatment Studies (11 papers), Estrogen and related hormone effects (6 papers) and Advanced Breast Cancer Therapies (4 papers). E. Mamounas is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Estrogen and related hormone effects (6 papers) and Advanced Breast Cancer Therapies (4 papers). E. Mamounas collaborates with scholars based in United States, United Kingdom and Spain. E. Mamounas's co-authors include Norman Wolmark, Jennifer Bryant, B. Fisher, Richard G. Margolese, Maureen Kavanah, Robert H. Oishi, Nikolay V. Dimitrov, Mirsada Begovič, Louis Fehrenbacher and Carl G. Kardinal and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

E. Mamounas

16 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18

2001 990 citations Norman Wolmark, E. Mamounas et al. JNCI Monographs profile →
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

1999 724 citations James J. Dignam, Norman Wolmark et al. The Lancet profile →
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831

2014 671 citations Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by E. Mamounas

Since Specialization

Citations

This map shows the geographic impact of E. Mamounas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Mamounas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Mamounas more than expected).

Fields of papers citing papers by E. Mamounas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Mamounas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Mamounas. The network helps show where E. Mamounas may publish in the future.

Co-authorship network of co-authors of E. Mamounas

This figure shows the co-authorship network connecting the top 25 collaborators of E. Mamounas. A scholar is included among the top collaborators of E. Mamounas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Mamounas. E. Mamounas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations 2025 ·Current Oncology ·(unknown), Julia Fedorova, (unknown), E. Mamounas, Sarfraz Ahmad, Sabrina Pavri	0
2	Cosmetic Outcome from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Julia White, Kathryn Winter, Reena S. Cecchini, Frank A. Vicini, D.W. Arthur, Robert R. Kuske, Rachel Rabinovitch, (unknown), Atif J. Khan, (unknown), Simona F. Shaitelman, Beryl McCormick, Thomas B. Julian, Leland Rogers, Harry D. Bear, Ivy A. Petersen, Gary Gustafson, Linda Grossheim, E. Mamounas, Patricia A. Ganz	29
3	Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) 2018 ·Breast Cancer Research and Treatment ·Jame Abraham, Humberto Caldera, Robert E. Coleman, Anthony Elias, Matthew P. Goetz, Muaiad Kittaneh, Elyse E. Lower, Reshma Mahtani, E. Mamounas, Mark D. Pegram, Hope S. Rugo, Lee S. Schwartzberg, Tiffany A. Traina, (unknown)	9
4	Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) 2018 ·Breast Cancer Research and Treatment ·(unknown), Jame Abraham, Robert E. Coleman, Anthony Elias, Frankie A. Holmes, Kevin Kalinsky, Muaiad Kittaneh, Elyse E. Lower, Reshma Mahtani, E. Mamounas, Mark D. Pegram, Charles L. Vogel	29
5	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value? 2017 ·The Breast ·Matti Aapro, Michelino De Laurentiis, (unknown), Enrique Bargalló‐Rocha, (unknown), László Landherr, Barbro Linderholm, E. Mamounas, Christos Markopoulos, Patrick Neven, Alexander Petrovsky, Roman Rouzier, Vincent T.H.B.M. Smit, Christer Svedman, Daniel J. Schneider, Christoph Thomssen, Miguel Martín	3
6	Effect of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer after prior adjuvant therapy with an aromatase inhibitor (AI): NRG Oncology/NSABP B-42 2017 ·The Breast ·E. Mamounas, Hanna Bandos, BC Lembersky, Charles E. Geyer, L. Fehrenbacher, (unknown), Seungmok Paik, Sandra M. Swain, Lawrence Wickerham, Norman Wolmark	2
7	P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen 2015 ·The Breast ·E. Mamounas, Norman Wolmark, (unknown), (unknown), Gong Tang, Farid Jamshidian, (unknown), Steven Shak, Seungmok Paik	1
8	An Update of the Credentialing Process for the NRG Oncology NSABP B-51 / RTOG 1304 Phase 3 Randomized Clinical Trial 2015 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Anil Tailor, J.M. Galvin, D Followill, (unknown), Thomas B. Julian, E. Mamounas, Julia White, (unknown), Simona F. Shaitelman, (unknown), Frank A. Vicini, Norman Wolmark, Walter J. Curran	0
9	Adoption of Multi-Gene Assays in HR +, HER2– Breast Cancer (BC) Patients in Europe: Results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) Survey 2014 ·Annals of Oncology ·Matti Aapro, Michelino De Laurentiis, E. Mamounas, Miguel Martín, Daniel Rea, Roman Rouzier, Vincent T.H.B.M. Smit, Christoph Thomssen	1
10	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 breakdown → 2014 ·Journal of Clinical Oncology ·Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, George W. Sledge, Charles E. Geyer, Silvana Martino, Priya Rastogi, Julie R. Gralow, Sandra M. Swain, Eric P. Winer, Gerardo Colón‐Otero, Nancy E. Davidson, E. Mamounas, Jo Anne Zujewski, Norman Wolmark	671
11	The Impact of Radiation Therapy on Lymphedema Risk and the Agreement Between Subjective and Objective Lymphedema Measures: NSABP B-32 Secondary Data Analysis 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Susan A. McCloskey, Hanna Bandos, TB Julian, Jacek A Kopec, Norman Wolmark, Stewart Anderson, David N. Krag, E. Mamounas, Patricia A. Ganz	1
12	Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after ∼ 5 Years of Tamoxifen. 2009 ·Cancer Research ·(unknown), E. Mamounas, R. Jakesz, Christos Markopoulos, Mitch Dowsett, R Peto, Jon Godwin, Christina Davies	10
13	Predictive Factors for Positive Non-Sentinel Nodes Following a Positive Sentinel Node Biopsy: NSABP B-32. 2009 ·Cancer Research ·Thomas B. Julian, Stuart Anderson, (unknown), (unknown), Peiyong Zheng, E. Mamounas, Ann L. Brown, (unknown), (unknown), J. P. Costantino, Norman Wolmark	0
14	Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors 2007 ·The American Journal of Surgery ·Peter Blumencranz, Pat W. Whitworth, Kenneth Deck, Anne Rosenberg, Douglas S. Reintgen, Peter D. Beitsch, Anees B. Chagpar, Thomas B. Julian, Sukamal Saha, E. Mamounas, Armando E. Giuliano, Rache M. Simmons	67
15	P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33 2007 ·The Breast ·CE Geyer, E. Mamounas, (unknown), Lawrence Wickerham, PA Ganz, Laura F. Hutchins, Andrew Eisen, (unknown), (unknown), Norman Wolmark	2
16	Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen 2004 ·JNCI Journal of the National Cancer Institute ·Worta McCaskill‐Stevens, John Wilson, John Bryant, E. Mamounas, Lucy Garvey, Joan James, Walter M. Cronin, D. L. Wickerham	20
17	Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18 breakdown → 2001 ·JNCI Monographs ·Norman Wolmark, (unknown), E. Mamounas, Jennifer Bryant, B. Fisher	990
18	Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial breakdown → 1999 ·The Lancet ·(unknown), James J. Dignam, Norman Wolmark, (unknown), (unknown), E. Mamounas, Roy E. Smith, Mirsada Begovič, Nikolay V. Dimitrov, Richard G. Margolese, Carl G. Kardinal, Maureen Kavanah, Louis Fehrenbacher, Robert H. Oishi	724
19	Primary colorectal non-Hodgkin's lymphoma 1994 ·Annals of Surgical Oncology ·Erna Busch, Miguel A. Rodrı́guez-Bigas, E. Mamounas, Maurice Barcos, Nicholas J. Petrelli	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact